Trial Profile
Treatment of Chronic Hepatitis C in HIV-Infected Patients With PegIntron Pen and Rebetol According to German Law (67 Abs 6 AMG).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 20 Jan 2012 Actual number of patients changed from 250 to 235 as reported by ClinicalTrials.gov.
- 20 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Dec 2011 Planned end date changed from 1 Nov 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.